Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD [chronic obstructive pulmonary disease].

Next Previous
Trial Profile

Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD [chronic obstructive pulmonary disease].

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 06 Mar 2019 Primary endpoint (Trough FEV1 response [L] for fixed-dose combination of tiotropium 5 mug with olodaterol 10 mug) has been met, according to the results published in the Advances in Therapy
    • 06 Mar 2019 Primary endpoint (Trough FEV1 response [L] for fixed-dose combination of tiotropium 5 mug with olodaterol 5 mug) has not been met, according to the results published in the Advances in Therapy
    • 06 Mar 2019 Primary endpoint (Trough FEV1 response [L] for fixed-dose combination of tiotropium 5 mug with olodaterol 2 mug) has not been met, according to the results published in the Advances in Therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top